Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v2-FR
Language English French
Date Updated 2020-08-15 2020-04-07
Drug Identification Number 02236926 02236926
Brand name ACYCLOVIR SODIUM INJECTION ACYCLOVIR SODIUM INJECTION
Common or Proper name Acyclovir Sodium Injection Acyclovir Sodium Injection
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients ACYCLOVIR ACYCLOVIR
Strength(s) 50MG 50MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size Vial 10 mL Vial 10 mL
ATC code J05AB J05AB
ATC description DIRECT ACTING ANTIVIRALS DIRECT ACTING ANTIVIRALS
Reason for shortage Shortage of an active ingredient. Shortage of an active ingredient.
Anticipated start date
Actual start date 2020-04-01 2020-04-01
Estimated end date Unknown
Actual end date 2020-08-14
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments On 50% Allocation effective April 1, 2020 Our stock of Acyclovir Sodium Injection 50 mg/mL, 10 mL and 20 mL vials is expected to deplete by August 14, 2020. The product will remain on reduced allocation until stock is depleted. On 50% Allocation effective April 1, 2020
Health Canada comments